{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-275856","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.368290+00:00","generated_at":"2026-06-22T12:54:57.947175+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products","bullets":["Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.","Launched AXIOFILL and AMNIOEFFECT for surgical recovery; obtained Japan reimbursement for EPIFIX.","Appointed Todd Newton interim CEO; new segment reporting for Wound & Surgical and Regenerative Medicine.","Advanced KOA registrational study with FDA, including Type B RMAT meeting and CMC filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-275856","json":"https://secwatch.observer/filing/0001193125-22-275856.json","markdown":"https://secwatch.observer/filing/0001193125-22-275856.md","text":"https://secwatch.observer/filing/0001193125-22-275856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/0001193125-22-275856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/d399649d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:54:57.947175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4048c216bb3e347d2726721fec667d7f485f4cb9","claim":"MIMEDX GROUP, INC. reported third quarter ended September 30, 2022 results: revenue $67.7 million, net income $8.4 million, EPS $ (0.09 ).","evidence_excerpt":"Key Third Quarter 2022 Financial Metrics • Net sales of $67.7 million for third quarter 2022, compared to $63.1 million for the prior year period. • Net loss of $8.4 million for third quarter 2022, compared to a net loss of $2.3 million for the prior year period. • Adjusted EBITDA 1 loss of $0.7 million for third quarter 2022, compared to a gain of $7.0 million for the prior year period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 67,689 $ 63,074 $ 193,466 $ 191,206 Net loss (8,426 ) (2,339 ) (29,783 ) (12,500 ) EBITDA 1 (6,097 ) 41 (22,971 ) (4,302 ) Adjusted EBITDA 1 (724 ) 7,022 (3,402 ) 15,117 Net loss per common share - basic $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 ) Net loss per common share - diluted $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/0001193125-22-275856-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$67.7 million"},{"label":"Net income","value":"$8.4 million"},{"label":"EPS","value":"$ (0.09 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}